Biomarker identification could help detect colorectal cancer early
Washington: A new non-invasive test has been developed that could help detect colorectal cancer in its early stages and thereby improve the chances of survival of people.
The test measures methylation of the SDC2 gene in tissues and blood sera and detected 87 percent of all stages of colorectal cancer cases (sensitivity) without significant difference between early and advanced stages, while correctly identifying 95 percent of disease-free patients (specificity).
There are other screening choices for colorectal cancer (CRC), including fecal occult blood testing (FOBT), fecal immunochemical testing, and colonoscopy.
Colonoscopy is the gold standard of CRC screening, but patient resistance - mostly due to the unpleasant preparation - has curbed widespread adoption.
FOBT is non-invasive but has limited sensitivity, particularly for early disease. A sensitive and specific non-invasive test using blood or stool could to be a more preferable option with the potential of saving many lives.
In their search for a biomarker that could be used for the early detection of CRC, investigators from Genomictree, Inc. and Yonsei University College of Medicine in Seoul, South Korea, performed DNA microarray analysis coupled with enriched methylated DNA using tissues from primary tumors and non-tumor tissues from 12 CRC patients.
After step-wise filtering, they found a set of genes that were highly methylated across all of the CRC tumors. Ultimately they identified one gene, SDC2, which encodes the membrane syndecan-2 protein, a protein that is known to participate in cell proliferation, cell migration, and is expressed in colon mesenchymal cells.
The methylation level of target region of SDC2 assessed in tumor tissue was found to be significantly higher than that from paired adjacent non-tumor tissue.
The next step was to clinically validate the biomarker by analyzing SDC2 methylation levels in primary tumors and paired-adjacent non-tumor tissue samples from 133 CRC patients. Investigators found that in the transcriptional regulatory region of the SDC2 gene, tumor samples showed significantly higher levels of methylation than the control samples.
SDC2 methylation positivity ranged from 92.9 percent to 100 percent when samples were stratified according to stages of cancer.
Further, investigators found that the SDC2 biomarker could be measured in serum samples from CRC patients and healthy individuals.
"The SDC2 methylation test was able to detect 92 percent for detection of stage I cancer patients indicating that SDC2 is suitable for early detection of CRC where therapeutic interventions have the greatest likelihood of curing the patient from the disease," first author TaeJeong Oh, PhD, said.
The results have been published in The Journal of Molecular Diagnostics.